Successes and setbacks of clinical gene therapy
The use of lentiviral haematopoietic stem cell gene therapy to treat hereditary immunodeficiencies has achieved great success in resolving the actual symptoms of the disease, but many of the patients that underwent therapy developed leukaemia later. Effective gene therapies involving gene shuttles that do not cause cancer are therefore required. The good news is that such therapies already exist.
© University of Konstanz
Andreas Marx - “Chemical Biology” of DNA polymerases
Whether inside the cell or in molecular biology laboratories, the synthesis of DNA would not be possible without DNA polymerases. The regulation and application of this versatile enzyme family is the subject of research carried out by Prof. Dr. Andreas Marx at the University of Konstanz in Southern Germany. In addition to basic research, Marx deals with the development of novel polymerases that can be used to solve biological issues and also can be used in the molecular diagnosis of diseases.
Bio-based Industries: first Call for Proposals
EU and industry leaders have launched a new European Joint Undertaking on Bio-based Industries (BBI). The aim is to trigger investments and create a competitive market for bio-based products and materials sourced locally and "Made in Europe". Here Europe's untapped biomass and wastes shoud be identified, to develop an emerging bioeconomy sector. Submission deadline for proposals is October 15th, 2014. more
IMI 2: Disease modifying therapy of Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 million people. The overall aim of the initiative is to significantly progress the understanding of T1DM disease by bringing together patients, health authorities, leading clinicians, and researchers from the areas of immunology, beta cell biology, and biomarker research from both academia and industry. The deadline for submitting proposals is November 12th, 2014. more